bornyl caffeate profile

bornyl caffeate: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5477248
CHEMBL ID	482354
CHEBI ID	157708
MeSH ID	M0298334

Synonym
nsc302300
bohlmann k1907
nsc-302300
(1,7,7-trimethylnorbornan-2-yl) (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
1,7,7-trimethylbicyclo[2.2.1]hept-2-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate
CHEBI:157708
(-)-bornyl-caffeate
(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl) (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
CHEMBL482354 ,
bornyl caffeate
bdbm50479627

Class	Description
hydroxycinnamic acid	Any member of the class of cinnamic acids carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Integrase	Human immunodeficiency virus 1	IC50 (µMol)	19.9000	0.0005	1.5443	10.0000	AID371216
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID371218	Cytotoxicity against human MCF7 cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines.
AID1161638	Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Synthesis and antitumor activity of feruloyl and caffeoyl derivatives.
AID371217	Cytotoxicity against human Bel7402 cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines.
AID1161634	Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Synthesis and antitumor activity of feruloyl and caffeoyl derivatives.
AID1161633	Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Synthesis and antitumor activity of feruloyl and caffeoyl derivatives.
AID1161635	Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Synthesis and antitumor activity of feruloyl and caffeoyl derivatives.
AID1161636	Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Synthesis and antitumor activity of feruloyl and caffeoyl derivatives.
AID371220	Cytotoxicity against human BCG823 cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines.
AID371216	Inhibition of HIV1 integrase by ELISA	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines.
AID1161637	Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Synthesis and antitumor activity of feruloyl and caffeoyl derivatives.
AID371219	Cytotoxicity against human A549 cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	2 (28.57)	29.6817
2010's	4 (57.14)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.72 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.80 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
alpha-pinene [no description available]	2.05	1	pinene	plant metabolite
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	2.04	1	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	2.04	1	caffeic acid	geroprotector; mouse metabolite
methyl caffeate methyl caffeate: from plant Gaillardia pulchella. methyl caffeate : An alkyl caffeate ester formed by the formal condensation of caffeic acid with methyl alcohol.	2.47	2	alkyl caffeate ester; methyl ester
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	2.47	2	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
bornyl ferulate bornyl ferulate: structure in first source	2.42	2	hydroxycinnamic acid
ethyl caffeate (E)-ethyl 3-(3,4-dihydroxyphenyl)prop-2-enoate: structure in first source. ethyl trans-caffeate : An ethyl ester resulting from the formal condensation of the carboxy group of trans-caffeic acid with ethanol.	2.47	2	alkyl caffeate ester; ethyl ester; hydroxycinnamic acid	anti-inflammatory agent; antineoplastic agent; metabolite
octadecyl caffeate caffeic acid n-octadecyl ester: isolated from Daphne acutiloba Rehd; structure in first source	2.47	2
benzyl caffeate benzyl caffeate: isolated from Liaoxi propolis	2.47	2
fukinolic acid fukinolic acid: also a carboxypeptidase A inhibitor; RN given for (S-(R,S))-isomer; structure in first source	2.03	1	hydroxycinnamic acid
propyl caffeate propyl caffeate: has antioxidant activity; structure in first source	2.47	2
octyl caffeate octyl caffeate: an antioxidant; structure in first source	2.47	2

Condition	Relationship Strength	Studies
Breast Cancer [description not available]	7.1	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.1	1
Adrenal Cancer [description not available]	2.1	1
Pheochromocytoma, Extra-Adrenal [description not available]	2.1	1
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	7.1	1

bornyl caffeate

Description

Cross-References

Synonyms (11)

Drug Classes (1)

Protein Targets (1)

Inhibition Measurements

Bioassays (11)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.72

Study Types

bornyl caffeate

Description

Cross-References

Synonyms (11)

Drug Classes (1)

Protein Targets (1)

Inhibition Measurements

Bioassays (11)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.72

Study Types

Related Drugs (12)

Related Conditions (5)